Dermatomyositis and polymyositis (myositis): vizsgálatok itt: Kanada
8 trials · From ClinicalTrials.gov, checked 2026. november 13.. Ask the study team whether a trial fits you.
- 1. fázisTaking peopleTesting an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
- Where
- Toronto
- Életkor
- 18 év and over
- People
- 300 worldwide
- Run by
- National Cancer Institute (NCI)
See details and how to joinNCT03816345 - 1. fázisTaking peopleA Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
- Where
- Montreal
- Életkor
- 18 év to 74 év
- People
- 66 worldwide
- Run by
- Allogene Therapeutics
See details and how to joinNCT07085104 - 3. fázisNot yet taking people in KanadaA Study to Understand How Nerandomilast Works in People With Active Idiopathic Inflammatory Myopathies
- Where
- Calgary, Sherbrooke, Vancouver
- Életkor
- 18 év and over
- People
- 270 worldwide
- Run by
- Boehringer Ingelheim
See details and how to joinNCT07789015 · EU 2026-526365-24-00 - 1. fázisTaking peopleA Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis.
- Where
- Hamilton, Sherbrooke
- Életkor
- 18 év to 70 év
- People
- 72 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06916806 · EU 2024-519015-34-00 - 1. fázisCsak meghívásosA Study of KITE-363 in Participants With Refractory Autoimmune Diseases
- Where
- Montreal, Ottawa
- Életkor
- 18 év and over
- People
- 52 worldwide
- Run by
- Kite, A Gilead Company
See details and how to joinNCT07038447 - 3. fázisTaking peopleA Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)
- Where
- Calgary, Montreal
- Életkor
- 18 év to 75 év
- People
- 240 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06455449 - 1. fázisTaking peoplePhase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)
- Where
- Edmonton, Montreal, Rimouski, Sherbrooke
- Életkor
- 18 év to 85 év
- People
- 144 worldwide
- Run by
- Chugai Pharmaceutical
See details and how to joinNCT06371417 · EU 2023-507692-21-00 - 1. fázisCsak meghívásosPhase 1b Long-term Extension Trial of RAY121 in Immunological Diseases (RAINBOW-LTE Trial)
- Where
- Sherbrooke
- Életkor
- 18 év to 85 év
- People
- 144 worldwide
- Run by
- Chugai Pharmaceutical
See details and how to joinNCT06723106